Pfizer Building $95 Million Production Plant in Suzhou

Pfizer has begun construction of a $95 million production facility in Suzhou for consumer health products. When finished, the facility will make Caltrate® dietary supplements and Centrum® multivitamins for China and other Asian markets. Other products will be added later. Pfizer also has plans to house an R&D facility on the site, which is home to another Pfizer plant that has been in operation for more than 20 years. More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //